Overview

Clinical Safety and Efficacy Evaluation of NanoLithium® NP03 in Patients With Mild-to-severe Alzheimer's Disease

Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This proof-of-concept study will assess safety, tolerance, and efficacy of NanoLithium® NP03 in patients with mild-to-severe Alzheimer's Disease (AD).
Phase:
Phase 2
Details
Lead Sponsor:
Medesis Pharma SA